The secured products patents are one each from South Korea (10-1386354), China (CN102639526) and Canada (CA 2737282) corresponding to the New Chemical Entities for the treatment of disorders associated with neurodegenerative diseases, the company said in a release adding that these patents are valid through 2029, 2029 and 2031, respectively.
The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are useful for treating Alzheimer's disease, Attention deficient hyperactivity disorder, Huntington's disease, Parkinson and Schizophrenia.
The stock opened at Rs 177 and touched a high of Rs 206 so far. Over 7.5 million shares were traded on both the stock exchanges so far.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
